We are dedicated to advancing new therapies to improve the lives of people living with sickle cell disease and other hemoglobinopathies.
IMR-687 addresses both the white cell and red cell aspects of sickle cell pathology in a safe and easy to use oral pill. We are currently enrolling a phase 2a clinical trial with IMR-687 in adult patients with sickle cell disease.
Imara deeply cares about its patients, their care-givers, and the broader community affected by sickle cell disease. See our events section to find out more about sponsorship and participation in sickle cell related events.